Embedded Files
Dr. Matt Boente MD has been, for most of his career, doing his part in the battle against ovarian cancer. He has diagnosed and treated patients, written extremely informative and detailed journals, joined research and screening teams, and as of late, started a series of blogs to help educate readers everywhere on ovarian cancer.
Dr. Matt Boente MD has been, for most of his career, doing his part in the battle against ovarian cancer. He has diagnosed and treated patients, written extremely informative and detailed journals, joined research and screening teams, and as of late, started a series of blogs to help educate readers everywhere on ovarian cancer.
For this blog, Dr. Matt Boente MD looks back at Avastin, which is a drug developed by Roche Group member Genentech and approved by the U.S. Food and Drug Administration (FDA) in 2018. The FDA approved Avastin (bevacizumab) in combination with chemotherapy. The drug follows the chemotherapy treatment for women with stage III or IV ovarian cancer, post-initial surgical resection.
For this blog, Dr. Matt Boente MD looks back at Avastin, which is a drug developed by Roche Group member Genentech and approved by the U.S. Food and Drug Administration (FDA) in 2018. The FDA approved Avastin (bevacizumab) in combination with chemotherapy. The drug follows the chemotherapy treatment for women with stage III or IV ovarian cancer, post-initial surgical resection.
The prevailing significance of Avastin is that women in the advanced stages of ovarian cancer are now given a new option for treatment, which has been proven to delay the progression of the disease effectively. It also marks the first treatment for women with stage III or IV ovarian cancer outside of chemotherapy. To put things in perspective, Dr. Matt Boente MD explains that ovarian cancer is the fifth leading cause of cancer-related deaths among women in the U.S., which makes this breakthrough is nothing short of monumental.
The prevailing significance of Avastin is that women in the advanced stages of ovarian cancer are now given a new option for treatment, which has been proven to delay the progression of the disease effectively. It also marks the first treatment for women with stage III or IV ovarian cancer outside of chemotherapy. To put things in perspective, Dr. Matt Boente MD explains that ovarian cancer is the fifth leading cause of cancer-related deaths among women in the U.S., which makes this breakthrough is nothing short of monumental.
Avastin has been approved for 10 different uses on six various kinds of cancer in the U.S.
Avastin has been approved for 10 different uses on six various kinds of cancer in the U.S.
Dr. Matt Boente MD is a specialist in obstetrics, gynecology ,and gynecologic oncology. Learn more about Dr. Boente by checking out this page.
Dr. Matt Boente MD is a specialist in obstetrics, gynecology ,and gynecologic oncology. Learn more about Dr. Boente by checking out this page.
Image source: contractpharma.com
Image source: lattoflaw.com
Page updated
Google Sites
Report abuse